ABSTRACT
Background Although several therapies have been evaluated for treatment of COVID-19, the morbidity and mortality in COVID-19 are still significant, and the need for safe and effective drugs remains high even after launch of vaccine programs.
Methods We conducted a double-blind, randomized, placebo-controlled trial with the novel oral angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients with C-reactive protein 50-150 mg/L but not needing mechanical ventilation. Patients were randomly assigned to oral C21 (100 mg twice daily) or placebo for 7 days in addition to standard of care, including glucocorticoids and remdesivir.
Results 106 patients underwent randomization (51 in the C21 group and 55 in the placebo group). At day 14 after start of treatment, the proportion of patients still requiring supplemental oxygen was significantly reduced by 90% in the C21 group compared to the placebo group (p=0.003). Moreover, fewer patients required mechanical ventilation (one C21 patient and four placebo patients), and C21 was associated with a numerical reduction in the mortality rate (one and three deaths in the C21 and placebo group, respectively). Treatment with C21 was safe and well tolerated.
Conclusions As studied in hospitalized COVID-19 patients, C21 on top of standard of care led to a clinically beneficial improvement in respiratory function compared to placebo, paving the way for a pivotal randomised controlled trial.
This study is registered at ClinicalTrials.gov with identifier NCT04452435.
Competing Interest Statement
G. Tornling reports personal fees from Vicore Pharma, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work; and holding of shares in Vicore Pharma. R. Batta reports grants from LifeArc Medical Research Charity, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work; In addition, R. Batta has a patent UK2004209.9 pending, a patent UK2009574.1 pending, and a patent US17/113,416 pending. J. Porter, has nothing to disclose. T. Bengtsson reports personal fees from Vicore Pharma, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work. K. Parmar and R. Kashiva report grants from Vicore Pharma, during the conduct of the study. A. Hallberg reports personal fees from Vicore Pharma, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work. A.K. Cohrt and K. Westergaard report personal fees from Vicore Pharma, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work. C.-J. Dalsgaard reports grants from LifeArc Medical Research Charity, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work; In addition, J. Dalsgaard has a patent UK2004209.9 pending, a patent UK2009574.1 pending, and a patent US17/113,416 pending. J. Raud reports grants from LifeArc Medical Research Charity, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work; In addition, J. Raud has a patent UK2004209.9 pending, a patent UK2009574.1 pending, and a patent US17/113,416 pending.
Clinical Trial
NCT04452435
Funding Statement
The trial was funded by Vicore Pharma and the independent medical research charity LifeArc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committees and registrations numbers: Noble Hospital Institutional Ethics Committee, Noble Hospitals Pvt. Ltd., Room No 5, Clinical Research Department Noble Annex, 153 A, Magarpatta City Road, Hadapsar Hadapsar, 411013 India, ECR/259/Inst/MH/2013/RR-19. Ethics Committee Metas Adventist Hospital Metas Adventist Hospital, 13-B, Nondh No 0363 To 0365, RS No21, Opp, Chowpati, Main Road, Athwalines CITY, Surat Gujarat, 395001 India, ECR/1323/Inst/GJ/2019. Sir Gangaram Hospital Ethics Committee Sir Ganga Ram Hospital, Ethics Committee, Sir Ganga Ram Hospital Old, Rajinder Nagar, New-Delhi, 110060 India, ECR/20/Inst/DL/2013/RR-2019. Institutional Ethics Committee, GMC, Nagpur Government Medical College and Hospital, Nagpur, Government Medical College, Medical Square, Hanuman Nagar, Nagpur Maharashtra, 440003 India, ECR/43/Inst/MH/2013/RR-19. Institutional Ethics Committee S.L., Raheja Hospital S.L. Raheja Hospital (A Fortis Associate) Raheja Rugnalaya Marg, Mahim (W), Mumbai MAHARASHTRA 400016 India, ECR/70/Inst/MH/2013/RR-19. The Institutional Ethics Committee, B.J. Medical College & Civil Hospital, B.J. Medical College & Civil Hospital, Office of Medical Superintendent Civil Hospital Ahmedabad, Ahmedabad Gujarat, 380016 India, ECR/72/Inst/GJ/2013/RR-19. Poona Medical Research Foundation Ruby Hall Clinic, 40, Sassoon road, Pune, Pune Maharashtra, 411001 India, ECR/24/Inst/MH/2013/RR-19. Unity Hospital Ethics Committee, Unity Trauma Center and Icu, N-4 Janki Park Society Aai Mata Road, Paravat Patiya, Surat Gujarat, 395010 India, ECR/1226/Inst/GJ/2019. Siddhi Hospital Laproscopy And IEC, Siddhi Hospital Laproscopy, Dhankawade-Patil Township, Pune Satara Road, Balaji Nagar, Dhankawadi Pune, Pune Maharashtra, 411043 India,ECR/1228/Inst/MH/2019. Rhythm Heart Institute Ethics Committee, Rhythm Heart Institute, Near Siddharth Bunglows Sama- Savli Road, VADODARA, Vadodara Gujarat, 390022 India, ECR/224/Inst/GJ/2013/RR-19.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available to researchers who provide a scientifically sound proposal. Proposals should be directed to carl-johan.dalsgaard@vicorepharma.com
